Our understanding of AAV is increasing
AAV (ANCA-associated vasculitis) is a group of progressive, rare, severe autoimmune diseases1,2
AAV can affect blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eyes, and heart.2
Read moreRecent updates
Rare Revolution Magazine – May edition
The latest edition of Rare Revolution Magazine is dedicated exclusively to ANCA-associated vasculitis. Rare Revolution is a digital magazine giving a voice to patients affected by RARE conditions and the charities that represent and support them – you can view the May edition here.
ECRD 2020
SEE ME. HEAR ME. Support for anyone living with, or affected by, ANCA-associated vasculitis (AAV).
PosterInvestigate AAV
Join the Rare Disease Investigation Team and put your expertise to the test in our interactive challenge. You’ll find it’s fully compatible with most desktop and mobile/tablet browsers (not for use on older versions of Internet Explorer or on Microsoft Edge).
Patient videos
Patient videos - view stories from Catherine, Jeremy, John & Susan and Shanali on the patient experience page.
Videos
ERA-EDTA 2019
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis.
PosterRenal damage in ANCA-associated vasculitis in incident and relapsing patients.
Slide deck
Electronic consent form
You should only register if you are a HCP based outside of the US.
References & footnotes
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
Jennette JC, et al. Arthritis Rheum 2013;65(1):1–11.
Yates M, Watts R. Clin Med (Lond) 2017;17(1):60–4.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
ERA-EDTA 2019 | EULAR 2019
NEW materials to download
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis. Poster >
High burden of disease for AAV patients in Germany - a claims study. Poster >
Economic burden of ANCA-associated vasculitis in Germany - a claims data study. Poster >
Adverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases. Poster >
Severity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data. Poster >
Renal damage in ANCA-associated vasculitis in incident and relapsing patients Slide deck >
ALSO NEW from UK Renal Week
Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients. Poster >
Introduction to AAV
AAV is a rare, severe small vessel vasculitis that affects multiple organs and has a high acute mortality risk1
Disease mechanism
The interaction between the activated alternative complement pathway, neutrophils and C5a is at the heart of vasculitic damage in AAV2
Current therapies
Treatment has improved but treatment-related complications remain common3
Investigate AAV
Take the interactive challenge to assess your understanding of AAV. Fully interactive version available on desktop only
References & footnotes
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Bekker P, et al. PLoS One 2016;11(10):e0164646.
Little MA, et al. Ann Rheum Dis 2010;69(6):1036−43.
Rutherford P, et al. Patient experience in ANCA-associated vasculitis evolves over time from diagnosis and both benefits and adverse impacts are felt with current therapy. Poster presented at: ACR/ARHP 2018, 19–24 October 2018, Chicago, IL, USA (abstract 2723).
Rutherford P, et al. Patient experience in anti-neutrophil cytoplasmic antibody-associated vasculitis – evolution with time and impact of current therapy. Draft publication.
Robson JC, et al. Rheumatol Int 2018;38(4):675–82.
Patient Support Organisations
Vasculitis International
Europe
www.vasculitis.eu
Suomen Vaskuliittiyhdistyksen ry
Finland
www.vaskuliittiyhdistys.fi
Association Vascularites
France/Belgium
www.association-vascularites.org
Selbsthilfe Vaskulitis e.V.
Germany
www.vaskulitisverein-rlp.de
Selbsthilfe Vaskulitis Mainz
Germany
vaskulitis-mainz@gmx.de
Vasculitis Ireland
Ireland
www.vasculitis-ia.org
Associazione Pazienti della Sindrome di Churg Strauss
Italy
www.apacs-egpa.org
Vasculitis Stichting
Netherlands
www.vasculitis.nl
Vasculitis UK
United Kingdom
www.vasculitis.org.uk
